A comprehensive study reveals how the ‘Alzheimer's gene’ (APOE ε4) affects the nature of the disease. It is not simply that those with the gene variant tend to be more impaired (in terms of both memory loss and brain damage) than those without. Different parts of the brain (and thus different functions) tend to be differentially affected, depending on whether the individual is a carrier of the gene or not. Carriers displayed significantly greater impairment on tests of memory retention, while noncarriers were more impaired on tests of working memory, executive control, and lexical access. Consistent with this, carriers showed greater atrophy in the mediotemporal lobe, and noncarriers greater atrophy in the frontoparietal area. The findings have implications both for diagnosis and treatment.
Alzheimer's expressed differently in carriers and noncarriers of the Alzheimer’s gene
Reference
Wolk, D. A., & Dickerson, B. C. (2010). Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease. Proceedings of the National Academy of Sciences, 107(22), 10256-10261. Retrieved from http://www.pnas.org/content/107/22/10256.abstract
Related News
Different kinds of physical activity improve brain volume & cut Alzheimer's risk
Data from 876 patients (average age 78) in the 30-year Cardiovascular Health Study show that virtually any type of aerobic physical activity can improve brain volume and reduce Alzheimer's risk.
Cognitive tests for MCI & Alzheimer's
Memory tests predict brain atrophy and Alzheimer's disease
Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), involving 230 cognitively normal individuals and 394 individuals with diagnosed with MCI on the basis of one episodic test, has found that performance on two tests markedly improved the identification of those whose MCI was more serious.
MCI can be a step on the road to Alzheimer's, but it can also be a reversible condition, and it’s obviously helpful to be able to distinguish the two.
Slower walking speeds linked to dementia risk
Data from the English Longitudinal Study of Aging, in which nearly 4,000 older adults (60+) had their walking speed assessed on two occasions in 2002-2003 and in 2004-2005, those with a slower walking speed were more likely to develop dementia in the next 10 years. Those who experienced a faster decline in walking speed over the two-year period were also more likely to develop dementia.
https://www.eurekalert.org/pub_releases/2018-03/ags-oaw032318.php
Brain network decay detected in early Alzheimer's
Submitted by Fiona McPherson
on
A multi-year study involving 207 healthy older adults, in which their spinal fluids were repeatedly sampled and their brains repeatedly scanned, has found that disruptions in the default mode network emerges about the same time as chemical markers of Alzheimer’s appear in the spinal fluid (decreased amyloid-beta and increased tau protein). The finding suggests not only that amyloid-beta and tau pathology affect default mode network integrity early on, but that scans of brain networks may be an equally effective and less invasive way to detect early disease.
Evidence for the benefits of meditation in fighting age-related cognitive decline
Submitted by Fiona McPherson
on
A review of meditation research reported in January last year concluded that there were insufficient good studies to allow us to say that meditation clearly improves attention and cognition. Studies from 2014 suggest three factors that might be part of the reason for inconsistent research findings:
Diabetes and tau tangles linked independently of Alzheimer's
A study involving older adults has found that diabetes was associated with higher levels of tau protein and greater brain atrophy.
The study involved 816 older adults (average age 74), of whom 397 had mild cognitive impairment, 191 had Alzheimer's disease, and 228 people had no cognitive problems. Fifteen percent (124) had diabetes.
Those with diabetes had greater levels of tau protein in the spinal and brain fluid regardless of cognitive status. Tau tangles are characteristic of Alzheimer's.
Smell tests provide early evidence of dementia
In the past few months, several studies have come out showing the value of three different tests of people's sense of smell for improving the accuracy of MCI and Alzheimer's diagnosis, or pointing to increased risk. The studies also add to growing evidence that a decline in sense of smell is an early marker for mild cognitive impairment and Alzheimer’s. Indeed, it appears that this sensory loss is a very early symptom, preceding even the shrinking of the entorhinal cortex (the first brain region to show signs of atrophy).
Alzheimer's produces early brain atrophy
Brain scans from over 4,000 people, across the age range (9 months to 94 years) and including 1,385 Alzheimer's patients, has revealed an early divergence between those who go on to develop Alzheimer’s and those who age normally. This divergence is seen in early atrophy of the hippocampus before age 40, and in the amygdala around age 40.
https://www.eurekalert.org/pub_releases/2019-03/c-ahd030819.php
Is soda bad for your brain, especially diet soda?
Data from the large and very long-running Framingham Heart Study has revealed that people who drink sugary drinks frequently are more likely to have poorer memory, smaller overall brain volume, and a significantly smaller hippocampus. Moreover, a second study found that those who drank diet soda daily were almost three times as likely to develop stroke and dementia over a 10-year period, compared to those who didn’t – suggesting that substituting artificial sweeteners for the sugar doesn’t make matters better.